Single-Dose Pharmacokinetics of Milvexian in Participants with Mild or Moderate Hepatic Impairment Compared with Healthy Participants

BACKGROUND: Patients with hepatic impairment receiving antithrombotic agents metabolized primarily through the liver can be at risk for bleeding. Milvexian (BMS-986177/JNJ-70033093) is a small-molecule, active-site inhibitor of activated Factor XI (FXIa). Modulation of FXI may provide systemic antic...

Descripción completa

Detalles Bibliográficos
Autores principales: Perera, Vidya, Abelian, Grigor, Li, Danshi, Wang, Zhaoqing, Zhang, Liping, Lubin, Susan, Chen, Wei, Bello, Akintunde, Murthy, Bindu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9249726/
https://www.ncbi.nlm.nih.gov/pubmed/35262846
http://dx.doi.org/10.1007/s40262-022-01110-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9249726/
https://www.ncbi.nlm.nih.gov/pubmed/35262846
http://dx.doi.org/10.1007/s40262-022-01110-9

Ejemplares similares